FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	205/10
vvasiiiigtoii,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								` '			' '									
1. Name ar Tendlei		f Reporting Person*						e and Tic	ker or Tra	ding S	symbol			neck all	applio	cable)	g Pers	son(s) to Iss		
					. L										irecto			10% O		
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/22/2023									X Officer (give title Other (spe below) below) General Counsel and Secretary						
C/O DO	CGO INC.													(ene	ral Couns	el an	d Secretar	y	
35 WEST 35TH STREET, FLOOR 6					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)							plicable							
(Street) NEW Y	ORK N	Υ	10001											X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(\$	State)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication														
	X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Tab	le I - Noi	n-Deriv	/ativ	e Se	curit	ies Ac	quired,	Dis	posed o	f, or Be	neficia	lly Ov	nec	ı				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (Instr. 5)			ed (A) or str. 3, 4 and	4 and Securit Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount	Amount (A) or (D)		Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 08/22				2/202	/2023		M ⁽¹⁾		10,000 A \$		\$1.5	9	33,088(2)			D				
Common Stock 08/22			2/202	2/2023		S ⁽³⁾		10,000 D \$		\$8.7	⁽⁴⁾ 23,088 ⁽²⁾		088(2)	D						
		-	Table II -									or Ben ble secu		y Own	ed					
1. Title of Derivative Security (Instr. 3) 2. Convers or Exerc Price of Derivativ Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		•	7. Title an of Securit Underlyin Derivative (Instr. 3 a	ties Ig Security	Deriv	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares							
Options to purchase Common	\$1.59	08/22/2023			M ⁽¹⁾			10,000	(5)		(5)	Common Stock	10,000	\$)	22,902 ⁰	(5)	D		

Explanation of Responses:

- 1. Exercise of options effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023 (the "10b5-1 Plan").
- 2. Reflects 23,088 restricted stock units ("RSUs") granted pursuant to the Issuer's 2021 Stock Incentive Plan (the "Plan"), which will vest on December 15, 2023. Each RSU represents the right to receive, upon vesting, one share of Common Stock, subject to the terms of the Plan.
- 3. Sale of shares effected pursuant to the 10b5-1 Plan.
- 4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$8.62 to \$9.00. Upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 5. On January 2, 2020, the Reporting Person was granted options (the "Options") exercisable for an aggregate of 32,902 shares of the Issuer's common stock ("Common Stock") at an aggregate exercise price of \$52,173, or \$1.59 per share. The Options vested in three equal annual installments beginning on November 12, 2020 and expire January 1, 2030, subject to the terms of the Option Agreement entered into with Ambulnz Inc. and assumed by the Issuer on November 5, 2021.

Remarks:

/s/ Ely D. Tendler

08/24/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.